Correlation Between Gilead Sciences and NLS Pharmaceutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Gilead Sciences and NLS Pharmaceutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Gilead Sciences and NLS Pharmaceutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Gilead Sciences and NLS Pharmaceutics AG, you can compare the effects of market volatilities on Gilead Sciences and NLS Pharmaceutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Gilead Sciences with a short position of NLS Pharmaceutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Gilead Sciences and NLS Pharmaceutics.

Diversification Opportunities for Gilead Sciences and NLS Pharmaceutics

-0.74
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Gilead and NLS is -0.74. Overlapping area represents the amount of risk that can be diversified away by holding Gilead Sciences and NLS Pharmaceutics AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on NLS Pharmaceutics and Gilead Sciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Gilead Sciences are associated (or correlated) with NLS Pharmaceutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of NLS Pharmaceutics has no effect on the direction of Gilead Sciences i.e., Gilead Sciences and NLS Pharmaceutics go up and down completely randomly.

Pair Corralation between Gilead Sciences and NLS Pharmaceutics

Given the investment horizon of 90 days Gilead Sciences is expected to generate 0.17 times more return on investment than NLS Pharmaceutics. However, Gilead Sciences is 5.82 times less risky than NLS Pharmaceutics. It trades about 0.03 of its potential returns per unit of risk. NLS Pharmaceutics AG is currently generating about -0.04 per unit of risk. If you would invest  7,955  in Gilead Sciences on September 12, 2024 and sell it today you would earn a total of  1,279  from holding Gilead Sciences or generate 16.08% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Gilead Sciences  vs.  NLS Pharmaceutics AG

 Performance 
       Timeline  
Gilead Sciences 

Risk-Adjusted Performance

10 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Gilead Sciences are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak essential indicators, Gilead Sciences may actually be approaching a critical reversion point that can send shares even higher in January 2025.
NLS Pharmaceutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days NLS Pharmaceutics AG has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Gilead Sciences and NLS Pharmaceutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Gilead Sciences and NLS Pharmaceutics

The main advantage of trading using opposite Gilead Sciences and NLS Pharmaceutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Gilead Sciences position performs unexpectedly, NLS Pharmaceutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NLS Pharmaceutics will offset losses from the drop in NLS Pharmaceutics' long position.
The idea behind Gilead Sciences and NLS Pharmaceutics AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Complementary Tools

Share Portfolio
Track or share privately all of your investments from the convenience of any device
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Bonds Directory
Find actively traded corporate debentures issued by US companies
Commodity Directory
Find actively traded commodities issued by global exchanges